10.22376/ijpbs.2019.10.1.p1-12 Volume 6 Issue 2 2015 (April - June) The purpose of this analysis was to compare the efficacy and safety of linezolid versus vancomycin in patients with nosocomial pneumonia, complicated skin & soft- tissue infections and sepsis by methicillin-resistant lessThan i greaterThan Staphylococcus aureus lessThan /i greaterThan (MRSA).This study was conducted on hospitalized patients of a tertiary care hospital in Kolkata, West Bengal. Out of 191 patients, 130 received linezolid 600 mg (IV or oral) every 12 hours and 61 received vancomycin 1 g every 12 hours IV. Clinical success rates at the end of the treatment were 94.6% and 90.16% for the linezolid and vancomycin groups respectively (p=0.2564) and microbiological eradication rates were 93.07% and 88.52% respectively (p=0.2901) showing no significant difference in the efficacy of two drugs. Drug related adverse events were reported in 0.7% and 1.63% of the patients treated with linezolid and vancomycin respectively with thrombocytopenia (3.84%) reported only in patients who received linezolid. Linezolid is as effective as vancomycin however intravenous or oral linezolid was well tolerated. NAVODHYA JINDAL, SONIA JAIN AND DHRITIMAN MAITRA Linezolid,Vancomycin,Gram-positive infections, Meticillin-resistant Staphylococcus aureus MRSA. 1087-1095